Longitudinal monitoring of metabolic alterations in cuprizone mouse model of multiple sclerosis using 1H-magnetic resonance spectroscopy

NeuroImage

Volumn 114, Issue , 2015, Pages 128-135

  Orije, Jasmien ^a   Kara, Firat ^a   Guglielmetti, Caroline ^a   Praet, Jelle ^a   Van der Linden, Annemie ^a   Ponsaerts, Peter ^a   Verhoye, Marleen ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cuprizone mouse model; Demyelination; Longitudinal; Multiple sclerosis; Proton magnetic resonance spectroscopy; Remyelination

Indexed keywords

CHOLINE; CREATINE; CUPRIZONE; GLUTAMIC ACID; N ACETYLASPARTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; FEMALE; GLIOSIS; LONGITUDINAL STUDY; METABOLITE; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REMYELINIZATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; METABOLISM; MYELIN SHEATH; PATHOLOGY;

ANIMALS; CORPUS CALLOSUM; CUPRIZONE; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN SHEATH; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84929705776     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2015.04.012     Document Type: Article

References (69)

1. Azami Tameh A., Clarner T., Beyer C., Atlasi M.A., Hassanzadeh G., Naderian H. Regional regulation of glutamate signaling during cuprizone-induced demyelination in the brain. Ann. Anat. 2013, 195:415-423.
2. Bianchi M.C., Tosetti M., Battini R., Manca M.L., Mancuso M., Cioni G., Canapicchi R., Siciliano G. Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance. Am. J. Neuroradiol. 2003, 24:1958-1966.
3. Bitsch A., Bruhn H., Vougioukas V., Stringaris A., Lassmann H., Frahm J., Bruck W. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am. J. Neuroradiol. 1999, 20:1619-1627.
4. Bottomley P.A. Spatial localization in NMR-spectroscopy in vivo. Ann. N. Y. Acad. Sci. 1987, 508:333-348.
5. Boumezbeur F., Mason G.F., de Graaf R.A., Behar K.L., Cline G.W., Shulman G.I., Rothman D.L., Petersen K.F. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J. Cereb. Blood Flow Metab. 2010, 30:211-221.
6. Bracken B.K., Rouse E.D., Renshaw P.F., Olson D.P. T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia. Psychiatry Res. 2013, 213:142-153.
7. Bucur A., Bernard A., Cudalbu C., Giraudon P., Graverdon-demilly D., Ratiney H., Cavassila S. Quantitative analysis of metabolic alterations in a mouse model of neuro-inflammation using in vivo MR Spectroscopy. Proc. Int. Soc. Magn. Reson. Med. 2008, 16:2179.
8. Burg M.B., Kwon E.D., Kultz D. Regulation of gene expression by hypertonicity. Annu. Rev. Physiol. 1997, 59:437-455.
9. Chard D.T., Griffin C.M., McLean M.A., Kapeller P., Kapoor R., Thompson A.J., Miller D.H. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002, 125:2342-2352.
10. Choi J.K., Dedeoglu A., Jenkins B.G. Application of MRS to mouse models of neurodegenerative illness. NMR Biomed. 2007, 20:216-237.
11. Choi J.K., Kustermann E., Dedeoglu A., Jenkins B.G. Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. Eur. J. Neurosci. 2009, 30:2143-2150.
12. Davie C.A., Hawkins C.P., Barker G.J., Brennan A., Tofts P.S., Miller D.H., McDonald W.I. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994, 117(Pt 1):49-58.
13. Davies S.E.C., Newcombe J., Williams S.R., McDonald W.I., Clark J.B. High-resolution proton NMR-spectroscopy of multiple-sclerosis lesions. J. Neurochem. 1995, 64:742-748.
14. De Stefano N., Filippi M. MR spectroscopy in multiple sclerosis. J. Neuroimaging 2007, 17(Suppl. 1):31S-35S.
15. De Stefano N., Matthews P.M., Ford B., Genge A., Karpati G., Arnold D.L. Short-term dichloroacetate treatment improves indexes of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995, 45:1193-1198.
16. De Stefano N., Bartolozzi M.L., Guidi L., Stromillo M.L., Federico A. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. J. Neurol. Sci. 2005, 233:203-208.
17. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004, 1012:60-65.
18. Denic A., Bieber A., Warrington A., Mishra P.K., Macura S., Rodriguez M. Brainstem 1H nuclear magnetic resonance (NMR) spectroscopy: marker of demyelination and repair in spinal cord. Ann. Neurol. 2009, 66:559-564.
19. Denic A., Johnson A.J., Bieber A.J., Warrington A.E., Rodriguez M., Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011, 18:21-29.
20. Duarte J.M., Gruetter R. Characterization of cerebral glucose dynamics in vivo with a four-state conformational model of transport at the blood-brain barrier. J. Neurochem. 2012, 121:396-406.
21. Duarte J.M., Lei H., Mlynarik V., Gruetter R. The neurochemical profile quantified by in vivo 1H NMR spectroscopy. NeuroImage 2012, 61:342-362.
22. Duarte J.M., Do K.Q., Gruetter R. Longitudinal neurochemical modifications in the aging mouse brain measured in vivo by 1H magnetic resonance spectroscopy. Neurobiol. Aging 2014, 35:1660-1668.
23. Filippi M., Absinta M., Rocca M.A. Future MRI tools in multiple sclerosis. J. Neurol. Sci. 2013, 331:14-18.
24. Foos T.M., Wu J.Y. The role of taurine in the central nervous system and the modulation of intracellular calcium homeostasis. Neurochem. Res. 2002, 27:21-26.
25. Franco-Pons N., Torrente M., Colomina M.T., Vilella E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol. Lett. 2007, 169:205-213.
26. Gruetter R. Automatic, localized in vivo adjustment of all 1st-order and 2nd-order shim coils. Magn. Reson. Med. 1993, 29:804-811.
27. Gudi V., Moharregh-Khiabani D., Skripuletz T., Koutsoudaki P.N., Kotsiari A., Skuljec J., Trebst C., Stangel M. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res. 2009, 1283:127-138.
28. Gustafsson M.C., Dahlqvist O., Jaworski J., Lundberg P., Landtblom A.M. Low choline concentrations in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. AJNR Am. J. Neuroradiol. 2007, 28:1306-1312.
29. Hennig J., Nauerth A., Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn. Reson. Med. 1986, 3:823-833.
30. Kipp M., Clarner T., Dang J., Copray S., Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol. 2009, 118:723-736.
31. Kirov I.I., Tal A., Babb J.S., Herbert J., Gonen O. Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology 2013, 80:39-46.
32. Kofke W.A., Hawkins R.A., Davis D.W., Biebuyck J.F. Comparison of the effects of volatile anesthetics on brain glucose metabolism in rats. Anesthesiology 1987, 66:810-813.
33. Kolasinski J., Stagg C.J., Chance S.A., Deluca G.C., Esiri M.M., Chang E.H., Palace J.A., McNab J.A., Jenkinson M., Miller K.L., et al. A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain 2012, 135:2938-2951.
34. Lange T., Zaitsev M., Buechert M. Correction of frequency drifts induced by gradient heating in 1H spectra using interleaved reference spectroscopy. J. Magn. Reson. Imaging 2011, 33:748-754.
35. Laule C., V.I.M., Kolind S.H., Li D.K.B., Traboulsee T.L., Moore G.R.W., Mac Kay A.L. Magnetic resonance imaging of myelin. Am. Soc. Exp. Neurother. 2007, 4:25.
36. Lindner M., Heine S., Haastert K., Garde N., Fokuhl J., Linsmeier F., Grothe C., Baumgartner W., Stangel M. Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathol. Appl. Neurobiol. 2008, 34:105-114.
37. Lindner M., Fokuhl J., Linsmeier F., Trebst C., Stangel M. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci. Lett. 2009, 453:120-125.
38. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
39. Lucchinetti C.F., Parisi J., Bruck W. The pathology of multiple sclerosis. Neurol. Clin. 2005, 23:77-105. (vi).
40. Lukovic D., Valdes-Sanchez L., Sanchez-Vera I., Moreno-Manzano V., Stojkovic M., Bhattacharya S.S., Erceg S. Brief report: astrogliosis promotes functional recovery of completely transected spinal cord following transplantation of hESC-derived oligodendrocyte and motoneuron progenitors. Stem Cells 2014, 32:594-599.
41. Mader I., Roser W., Kappos L., Hagberg G., Seelig J., Radue E.W., Steinbrich W. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2years during a clinical pharmacological study. Am. J. Neuroradiol. 2000, 21:1220-1227.
42. Mandal P.K. In vivo proton magnetic resonance spectroscopic signal processing for the absolute quantitation of brain metabolites. Eur. J. Radiol. 2012, 81:e653-e664.
43. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack C.R., Ugurbil K., Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11906-11910.
44. Mason J.L., Jones J.J., Taniike M., Morell P., Suzuki K., Matsushima G.K. Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J. Neurosci. Res. 2000, 61:251-262.
45. Mason J.L., Langaman C., Morell P., Suzuki K., Matsushima G.K. Episodic demyelination and subsequent remyelination within the murine central nervous system: changes in axonal calibre. Neuropathol. Appl. Neurobiol. 2001, 27:50-58.
46. Matsushima G.K.M.P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 2001, 11:10.
47. Morell P., Barrett C.V., Mason J.L., Toews A.D., Hostettler J.D., Knapp G.W., Matsushima G.K. Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol. Cell. Neurosci. 1998, 12:220-227.
48. Near J., Edden R., Evans C.J., Paquin R., Harris A., Jezzard P. Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain. Magn. Reson. Med. 2014, 10.1002/mrm.25094.
49. Oh J., Pelletier D., Nelson S. Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging. Arch. Neurol. 2004, 61:1081-1086.
50. Oz G., Nelson C.D., Koski D.M., Henry P.G., Marjanska M., Deelchand D.K., Shanley R., Eberly L.E., Orr H.T., Clark H.B. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 2010, 30:3831-3838.
51. Pascual J.M., Solivera J., Prieto R., Barrios L., Lopez-Larrubia P., Cerdan S., Roda J.M. Time course of early metabolic changes following diffuse traumatic brain injury in rats as detected by (1)H NMR spectroscopy. J. Neurotrauma 2007, 24:944-959.
52. Pfeuffer J., Tkac I., Provencher S.W., Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time H-1 NMR spectra of the rat brain. J. Magn. Reson. 1999, 141:104-120.
53. Provencher S.W. Estimation of metabolite concentrations from localized in-vivo proton NMR-spectra. Magn. Reson. Med. 1993, 30:672-679.
54. Provencher S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001, 14:260-264.
55. Provencher S.W. LCModel & LCMgui user's manual http://s-provencher.com/pages/lcm-manual.shtml.
56. Ramadan S., Lin A., Stanwell P. Glutamate and glutamine: a review of in vivo MRS in the human brain. NMR Biomed. 2013, 26:1630-1646.
57. Saneto R.P., Friedman S.D., Shaw D.W. Neuroimaging of mitochondrial disease. Mitochondrion 2008, 8:396-413.
58. Sijens P.E., Mostert J.P., Oudkerk M., De Keyser J. (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur. Radiol. 2006, 16:489-495.
59. Skripuletz T.G.V., Hackstette D., Stangel M. De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol. Histopathol. 2011, 26:13.
60. Srinivasan R., Sailasuta N., Hurd R., Nelson S., Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3T. Brain 2005, 128:1016-1025.
61. Stidworthy M.F., Genoud S., Suter U., Mantei N., Franklin R.J.M. Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol. 2003, 13:329-339.
62. Tkac I., Gruetter R. Methodology of H NMR spectroscopy of the human brain at very high magnetic fields. Appl. Magn. Reson. 2005, 29:139-157.
63. Tkac I., Starcuk Z., Choi I.Y., Gruetter R. In vivo H-1 NMR spectroscopy of rat brain at 1ms echo time. Magn. Reson. Med. 1999, 41:649-656.
64. Tkac I., Henry P.G., Andersen P., Keene C.D., Low W.C., Gruetter R. Highly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4T. Magn. Reson. Med. 2004, 52:478-484.
65. Tkac I., Dubinsky J.M., Keene C.D., Gruetter R., Low W.C. Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy. J. Neurochem. 2007, 100:1397-1406.
66. Tourbah A., Stievenart J.L., IbaZizen M.T., Zannoli G., LyonCaen O., Cabanis E.A. In vivo localized NMR proton spectroscopy of normal appearing white matter in patients with multiple sclerosis. J. Neuroradiol. 1996, 23:49-55.
67. Venturini G. Enzymic activities and sodium, potassium and copper concentrations in mouse brain and liver after cuprizone treatment in vivo. J. Neurochem. 1973, 21:1147-1151.
68. Xie M.Q., Tobin J.E., Budde M.D., Chen C.I., Trinkaus K., Cross A.H., McDaniel D.P., Song S.K., Armstrong R.C. Rostrocaudal analysis of corpus callosum demyelination and axon damage across disease stages refines diffusion tensor imaging correlations with pathological features. J. Neuropathol. Exp. Neurol. 2010, 69:704-716.
69. Xuan Y., Yan G., Peng H., Wu R., Xu H. Concurrent changes in 1H-MRS metabolites and antioxidant enzymes in the brain of C57BL/6 mouse short-termly exposed to cuprizone: possible implications for schizophrenia. Neurochem. Int. 2014, 69:20-27.